Exxon stock pops to a fresh 52-week high as oil rebounds; traders eye valuation and geopolitics
4 February 2026
2 mins read

Exxon stock pops to a fresh 52-week high as oil rebounds; traders eye valuation and geopolitics

NEW YORK, Feb 3, 2026, 17:53 EST — After-hours trading

  • Exxon shares surged 3.85%, closing at $143.73 and outpacing the wider market.
  • Rising U.S.-Iran tensions pushed oil prices up, boosting energy stocks.
  • A broker downgrade pointed to valuation concerns even as Exxon released fresh proxy-vote outreach materials.

Exxon Mobil shares jumped 3.85% to finish Tuesday at $143.73, hitting a new 52-week peak, then held steady after hours. Trading volume surged past 37 million shares—more than twice the usual amount. (MarketWatch)

This shift is significant as Exxon is once again acting like a macro play: it rallies when crude prices spike, and takes a hit when they falter. Oil has been volatile lately, pushing traders to lean into large, liquid energy stocks for quick exposure. (Reuters)

This comes as Wall Street debates if energy’s rally has peaked. BNP Paribas downgraded Exxon to “underperform,” signaling expectations that the stock will trail the market or sector. The bank pointed to valuation concerns, even though Exxon’s quarterly results were solid. (TipRanks)

Energy led the S&P 500 sectors Tuesday, climbing 3.3% even as the broader index dropped 0.84%. Brent crude closed at $67.33 a barrel, with U.S. crude finishing at $63.21. Reuters noted that recent tensions between the United States and Iran have sparked fresh concerns about supply risks. (Reuters)

Monday’s session took a sharp turn. Oil prices dropped over 4% after signals of easing U.S.-Iran tensions surfaced, while a firmer dollar weighed on commodities broadly, noted Commonwealth Bank of Australia strategist Vivek Dhar. (Reuters)

Exxon popped up in proxy filings again. On Feb. 2, the company revealed outreach plans for a “Voluntary Retail Voting Program” designed to boost participation from individual investors. It noted that nearly 40% of its shareholders are individuals, yet usually only around 25% of those shares get voted at the annual meeting.

The filing featured a script presenting the program as a tool to streamline proxy voting — where shareholders cast ballots on matters like director elections or policy proposals. Exxon noted investors could choose to have their shares voted according to board recommendations, while still retaining the option to opt out or override those votes.

For traders, the stock remains tied to crude prices and the risk premium baked into the barrel. Yet the proxy battle serves as a sharp reminder: governance clashes can flare up fast at mega-cap energy giants, pulling unwanted headlines into the mix at the worst possible times.

Several risks loom for the bulls. Should the geopolitical premium ease and oil prices drop, Exxon’s recent gains could unravel quickly. The valuation question remains, too, with the stock trading at a lofty price-to-earnings multiple — meaning its share price is high compared to its profits. (TipRanks)

Exxon led the pack Tuesday, pushing ahead as Chevron climbed 2.30% and ConocoPhillips gained 3.07%. Investors shifted funds into energy stocks, while tech shares dragged down Wall Street. (MarketWatch)

Wednesday’s session will focus on whether Exxon can maintain gains above breakout points amid oil price moves driven by fresh U.S.-Iran news — and if new proxy filings bring another twist to this geopolitically charged stock. (Reuters)

Stock Market Today

  • Novo Nordisk Shares Drop 14.75% on Weaker 2026 Outlook Amid Obesity-Drug Market Pressure
    February 3, 2026, 8:15 PM EST. Novo Nordisk shares plunged 14.75% to $50.33 after management projected a 2026 sales and profit decline, despite recent strong results. The Danish drugmaker faces pricing pressure and rising competition in obesity treatments, particularly in the U.S. Trading volume surged to 67.7 million shares, nearly triple the average. The company forecasts a 5%-13% sales drop in 2026, driven by price cuts, patent expirations, and intensified rivalry. Meanwhile, pharma peers Eli Lilly and Novartis also closed lower amid broader sector weakness. Investors will monitor Novo Nordisk's strategy expansion and new therapies like the Wegovy pill as key to restoring growth momentum.
Intel stock rises after CEO flags a new GPU push to take on Nvidia
Previous Story

Intel stock rises after CEO flags a new GPU push to take on Nvidia

Western Digital stock jumps after $4 billion buyback boost and 100TB drive roadmap
Next Story

Western Digital stock jumps after $4 billion buyback boost and 100TB drive roadmap

Go toTop